LEXICON PHARMACEUTICALS ANNOUNCES TOPLINE PHASE 1 CLINICAL RESULTS FOR LX2761 IN DIABETES

December 21, 2018 by Website Admin in

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes.

Tweet

Share

Pin it

Previous StoryAnti-fibrotic Activity of AVID200, a novel TGF-beta 1 & 3 inhibitor, to be Featured in an Oral Presentation at the Upcoming Keystone Symposia on NASH and NAFLD Next StoryNature publication reports first-in-human trial for a personalized cancer immunotherapy